A pill that can shrink and potentially eliminate pancreatic tumors is being hailed as the most revolutionary cancer treatment in decades.
In one in 12 patients who received the drug, daraxonrasib, during a trial, the cancer became undetectable and the tumors stopped growing in almost all 61 patients. Trial participants had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.
Although doctors said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay, they said it is encouraging news because it appears it would offer patients more time, even if it does not lead to complete remission.
Half of people diagnosed with pancreatic cancer die within three months, and only about 3 percent of patients survive five years when the disease spreads to other organs. It has the lowest survival rate of all common cancers in the UK and has an equally poor prognosis globally.
Patients were followed for an average of a year and a half during the trial and some did not see the cancer return during this time. Longer studies will be conducted to see if any of the cancers can be put into remission. During the trial, tumors stopped growing in 90% of patients, just over 60% of patients saw their tumors shrink or disappear, and in about 8% of patients, tumors became undetectable on CT scan.
One year after the start of treatment, 76.6% of patients were alive; typically, 40 to 45% of patients receiving chemotherapy alone survive one year.
Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the results, said “this is the closest we’ve come to a cure,” adding that he had never seen so many tumors disappear in patients whose cancer had spread.
He presented the results at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. “We are starting to see not only a higher percentage tumor response rate, but also deeper responses and a near doubling of the duration of disease control, which could eventually translate into longer survival,” he said.
“The median follow-up is 18 months. Imagine, in 18 months on average, your disease disappears on the scan… it’s the closest you can get to complete remission… it’s incredible.”
Daraxonrasib is a KRAS inhibitor treatment, which works by locking and disabling certain mutations found in most pancreatic cancers. These mutations lead to tumor growth.
It is hoped the treatment could work for dozens of other cancers, as they may have similar mutations.
Michelle Mitchell, chief executive of Cancer Research UK, said more research was needed, but added: “This is the biggest step forward we have seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult to treat cancers.
“These results raise the exciting possibility that this advance could potentially pave the way for the treatment of other cancers with Kras gene mutations. Further trials are now needed before this treatment can be evaluated for use on the NHS and despite this advance, survival for pancreatic cancer is still very low.”
Gn Health
